Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
出版年份 2021 全文链接
标题
Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
作者
关键词
-
出版物
Cancers
Volume 13, Issue 14, Pages 3556
出版商
MDPI AG
发表日期
2021-07-16
DOI
10.3390/cancers13143556
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series
- (2021) Amir Iravani et al. Clinical Genitourinary Cancer
- Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake
- (2021) Matteo Bauckneht et al. Diagnostics
- Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis
- (2021) Swayamjeet Satapathy et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer
- (2021) Nicholas Mitsiades et al. ENDOCRINE-RELATED CANCER
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
- (2021) Mike Wenzel et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Precision Medicine Approach in Prostate Cancer
- (2020) Majid Assadi et al. CURRENT PHARMACEUTICAL DESIGN
- New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide
- (2020) Florian Rosar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
- (2020) Robert Seifert et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
- (2020) Naoya Nagaya et al. PLoS One
- GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome
- (2020) Salma Meziou et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
- (2020) Michael S Hofman et al. LANCET
- Metastatic castration-resistant prostate cancer
- (2020) Lugeng He et al. MEDICINE
- PSMA PET–CT improves staging
- (2020) David Killock Nature Reviews Clinical Oncology
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review
- (2020) Raffaele Ratta et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Clinical aspects of mCRPC management in patients treated with radium-223
- (2020) Elisa Lodi Rizzini et al. Scientific Reports
- New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer
- (2020) Ching-Yu Lin et al. Translational Andrology and Urology
- New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
- (2020) Gaetano Aurilio et al. Cells
- The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
- (2020) Daniel J. Turnham et al. Cells
- Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target
- (2020) Amelie Heesch et al. Cells
- BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
- (2020) Carlo Messina et al. Journal of Oncology
- First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients
- (2020) Vikas Prasad et al. JOURNAL OF NUCLEAR MEDICINE
- Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
- (2020) Andrew J. Armstrong et al. JOURNAL OF UROLOGY
- Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
- (2020) Nattakorn Dhiantravan et al. European Urology Focus
- Radionuclide Therapy of Metastatic Prostate Cancer
- (2019) Clemens Kratochwil et al. SEMINARS IN NUCLEAR MEDICINE
- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands
- (2019) Gordon Winter et al. NUCLEAR MEDICINE AND BIOLOGY
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
- (2019) Alec Paschalis et al. EUROPEAN UROLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function
- (2019) Bin Gui et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.
- (2019) Cattrini et al. Cancers
- Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play
- (2019) Patel et al. Cancers
- Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
- (2019) Leonard J. Appleman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients
- (2019) Sofia Vaz et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Additional local therapy of liver metastases in mCRPC patients receiving systemic PSMA targeted therapy
- (2019) Robert Seifert et al. JOURNAL OF NUCLEAR MEDICINE
- Response prediction of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH.
- (2019) Hendrik Rathke et al. JOURNAL OF NUCLEAR MEDICINE
- Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies
- (2019) Amir Iravani et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for FDG imaging of PSMA-suppressed tumors
- (2019) Martin K. Bakht et al. JOURNAL OF NUCLEAR MEDICINE
- The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
- (2019) Nusrat J. Begum et al. Scientific Reports
- Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004–2014
- (2018) Jun Li et al. ANNALS OF EPIDEMIOLOGY
- BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy
- (2018) Hojjat Ahmadzadehfar et al. CLINICAL NUCLEAR MEDICINE
- Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
- (2018) Ali Afshar-Oromieh et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
- (2018) Denise S. O’Keefe et al. JOURNAL OF NUCLEAR MEDICINE
- The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for177Lu-Labeled PSMA Peptides
- (2018) Nusrat J. Begum et al. JOURNAL OF NUCLEAR MEDICINE
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- [177Lu]PSMA-617 radionuclide therapy shows promise
- (2018) Conor A. Bradley Nature Reviews Urology
- Clinical implications of PTEN loss in prostate cancer
- (2018) Tamara Jamaspishvili et al. Nature Reviews Urology
- PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
- (2018) Sara Bravaccini et al. Scientific Reports
- Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT
- (2018) Thomas J.W. Klein Nulent et al. Oral Surgery Oral Medicine Oral Pathology Oral Radiology
- PSMA Theranostics: Current Status and Future Directions
- (2018) Kambiz Rahbar et al. Molecular Imaging
- PI3K pathway in prostate cancer: All resistant roads lead to PI3K
- (2018) Soonbum Park et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
- (2018) Katharina Lückerath et al. EJNMMI Research
- Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis
- (2018) Marie Christine Hupe et al. Frontiers in Oncology
- Neuroendocrine differentiation of prostate cancer leads to PSMA suppression
- (2018) Martin K Bakht et al. ENDOCRINE-RELATED CANCER
- Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
- (2017) Kambiz Rahbar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
- (2017) Finn Edler von Eyben et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The Diagnosis and Treatment of Prostate Cancer
- (2017) Mark S. Litwin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors
- (2017) Charalambos Kaittanis et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- (2017) Matthias Eiber et al. JOURNAL OF NUCLEAR MEDICINE
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
- (2017) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer
- (2017) Leslie Ann Caromile et al. Science Signaling
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
- (2017) Mohammad Asim et al. Nature Communications
- PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer
- (2017) Leslie Ann Caromile et al. Science Signaling
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
- (2016) Kambiz Rahbar et al. CLINICAL NUCLEAR MEDICINE
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- MP66-19 PROSTATE-SPECIFIC MEMBRANE ANTIGEN INTERACTS WITH DIETARY FOLATE TO FACILITATE PROSTATE CARCINOGENESIS AND PROGRESSION
- (2016) Dean Bacich et al. JOURNAL OF UROLOGY
- Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment
- (2016) D. P. Nguyen et al. MOLECULAR CANCER RESEARCH
- Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer
- (2016) Tobias M. Gorges et al. Oncotarget
- Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
- (2016) Till Wüstemann et al. Theranostics
- Altered calcium signaling in cancer cells
- (2015) Teneale A. Stewart et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Expectant management for men with early stage prostate cancer
- (2015) Christopher P. Filson et al. CA-A CANCER JOURNAL FOR CLINICIANS
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beyond PSA: Managing Modern Therapeutic Options in Metastatic Castration-Resistant Prostate Cancer
- (2015) Fatima H. Karzai et al. SOUTHERN MEDICAL JOURNAL
- Prostate cancer: measuring PSA
- (2014) C. Pezaro et al. INTERNAL MEDICINE JOURNAL
- Correction: The Prostate Specific Membrane Antigen Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways1
- (2014) Marco Colombatti et al. PLoS One
- Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer
- (2014) Jose D. Murga et al. PROSTATE
- Signaling pathway switch in breast cancer
- (2013) Arnaud Guille et al. Cancer Cell International
- Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer
- (2013) J. L. Kasperzyk et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
- (2013) Rhonda L Bitting et al. ENDOCRINE-RELATED CANCER
- Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue
- (2013) M. Salemi et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- mTOR-Controlled Autophagy Requires Intracellular Ca2+ Signaling
- (2013) Jean-Paul Decuypere et al. PLoS One
- Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA)
- (2013) Duanwen Shen et al. PLoS One
- The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research
- (2013) Benjamin T. Ristau et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Opposing Roles of Folate in Prostate Cancer
- (2013) Kevin J. Rycyna et al. UROLOGY
- The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man
- (2012) Naomi L. Sharma et al. CANCER CELL
- Dual Roles of PARP-1 Promote Cancer Growth and Progression
- (2012) M. J. Schiewer et al. Cancer Discovery
- Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
- (2011) R Mukherjee et al. BRITISH JOURNAL OF CANCER
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Characterising the castration-resistant prostate cancer population: a systematic review
- (2011) M. Kirby et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
- (2011) M. J. Evans et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer
- (2010) Sarah Minner et al. PROSTATE
- LHRH-Analoga zur Androgendeprivation beim Prostatakarzinom. Eine Evidenzlevelanalyse
- (2009) J. Pfitzenmaier et al. AKTUELLE UROLOGIE
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate-specific membrane antigen expression in regeneration and repair
- (2008) Ilyssa O Gordon et al. MODERN PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now